8-K: Prothena Reports Q4/FY25 Results, Advances Clinical Pipeline

Prothena reported its fourth quarter and full year 2025 financial results, highlighting significant advancements in its partnered clinical programs and providing 2026 financial guidance.

Summary

• Net cash used in operating and investing activities was $23.3 million for Q4 2025 and $163.7 million for the full year 2025.
• The company ended 2025 with $308.4 million in cash, cash equivalents, and restricted cash.
• Prothena expects full year 2026 net cash used in operating and investing activities to be $50 to $55 million, projecting an ending cash balance of approximately $255 million (midpoint).
• The 2026 financial guidance does not include the potential to earn up to $105 million in aggregate clinical milestone payments from strategic partners.
• Roche initiated the Phase 3 PARAISO trial for prasinezumab in early-stage Parkinson's disease in Q4 2025, with primary completion expected in 2029.
• Novo Nordisk initiated the Phase 3 CLEOPATTRA trial for coramitug in ATTR amyloidosis with cardiomyopathy in Q4 2025, with primary completion expected in 2029.
• Bristol Myers Squibb fully enrolled the Phase 2 TargetTau-1 trial for BMS-986446 in early Alzheimer's disease, with primary completion expected in 1H 2027.
• BMS-986446 received Fast Track designation from the U.S. FDA for the treatment of Alzheimer's disease.
• Shareholders approved a reduction in share capital on November 19, 2025, to create distributable reserves for a potential share redemption program in 2026.
• Net loss for Q4 2025 was $21.6 million and for the full year 2025 was $244.1 million.
• Total revenue for Q4 2025 was $21 thousand and for the full year 2025 was $9.7 million.
• Research and development (R&D) expenses decreased to $14.6 million for Q4 2025 and $134.9 million for the full year 2025.
• General and administrative (G&A) expenses decreased to $12.6 million for Q4 2025 and $59.4 million for the full year 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update, driven by significant clinical trial advancements and potential future milestones, despite a weaker financial performance in 2025 due to one-off items and reduced collaboration revenue. The potential for a share redemption program also adds a positive note for shareholders.

Positives

• Multiple partnered programs (prasinezumab, coramitug) advanced to Phase 3 clinical trials, indicating significant progress in the pipeline.
• BMS-986446 fully enrolled its Phase 2 trial and received FDA Fast Track designation, potentially accelerating its development and review.
• Potential to earn up to $105 million in clinical milestone payments in 2026 from strategic partners Novo Nordisk and Bristol Myers Squibb.
• Significant reduction in R&D expenses ($134.9 million in FY25 vs. $222.5 million in FY24) and G&A expenses ($59.4 million in FY25 vs. $67.2 million in FY24) due to lower clinical trial, personnel, manufacturing, and consulting costs.
• Shareholder approval for capital reduction provides flexibility for a potential share redemption program in 2026, offering a potential return of capital to shareholders.
• Roche has stated that prasinezumab has peak sales potential greater than $3.5 billion, highlighting its significant market opportunity.
• Preclinical data on the TDP-43 CYTOPE program demonstrates the potential of Prothena's technology to target intracellular disease pathways.

Negatives

• Net loss for the full year 2025 significantly increased to $244.1 million, compared to $122.3 million for the full year 2024.
• Total revenue for the full year 2025 decreased substantially to $9.7 million, compared to $135.2 million for the full year 2024, primarily due to the absence of an $80 million upfront payment received in 2024.
• The full year 2025 net loss includes $30.1 million in restructuring charges associated with the discontinuation of the birtamimab program and a reduction in workforce.
• The full year 2025 net loss also includes a $43.2 million net non-cash income tax expense to book a full valuation allowance against federal deferred tax assets.
• The PRX012 Phase 1 ASCENT clinical program showed robust plaque clearance but was associated with non-competitive rates of ARIA-E, leading to development of PRX012-TfR in preclinical studies and exploration of partnership opportunities instead of direct advancement.

Risks

• Uncertainties related to the completion of operational and financial closing procedures, audit adjustments, and other developments that may require adjustments to the preliminary financial results.
• Risks associated with the continued advancement of the preclinical and clinical pipeline, including the potential and advancement of CYTOPE technology and expected milestones.
• Uncertainties regarding the treatment potential, designs, proposed mechanisms of action, and potential administration of investigational therapeutics like prasinezumab, coramitug, BMS-986446, PRX019, TDP-43 CYTOPE, and PRX012-TfR.
• Risks related to the timing of reporting data from preclinical studies and clinical trials.
• Projections regarding peak sales and patient population for prasinezumab may not be accurate.
• Uncertainties about the timing of and amounts the company may receive under collaborations with Novo Nordisk and Bristol Myers Squibb.
• Anticipated net cash burn from operating and investing activities for 2026 and expected cash balance at the end of 2026 could differ materially from projections.
• The potential to return capital to shareholders via a share redemption program is subject to the discretion of the Board of Directors and the company's then-current financial condition.
• The company undertakes no obligation to update publicly any forward-looking statements contained in the press release.

Future Outlook

Prothena expects full year 2026 net cash used in operating and investing activities to be $50 to $55 million, with an estimated ending cash balance of approximately $255 million. This guidance does not include potential clinical milestone payments of up to $105 million from strategic partners in 2026. The company anticipates further advancements in its partnered clinical programs, including decisions on PRX019 and primary completions of Phase 3 trials in 2029, and expects to share more preclinical data later in 2026.

Management Comments

• "In 2025, our partner Roche initiated the Phase 3 PARAISO clinical trial evaluating prasinezumab in early Parkinson's disease and Novo Nordisk initiated the Phase 3 CLEOPATTRA clinical trial evaluating coramitug in ATTR amyloidosis with cardiomyopathy, both with primary completions expected in 2029."
• "We expect our partner Bristol Myers Squibb to decide on the potential advancement of PRX019 in 2026 and to complete the ongoing Phase 2 TargetTau-1 clinical trial evaluating BMS-986446 in early Alzheimer's in 1H 2027."
• "These partnered programs have the potential to earn up to approximately $3 billion in future aggregate milestones in addition to potential future royalties."
• "We also unveiled our proprietary CYTOPE technology with presentations at scientific congresses highlighting preclinical data from our TDP-43 CYTOPE program."
• "We expect to share more data from our preclinical programs later this year."

Industry Context

StockSavvy.ai notes that Prothena operates in the highly competitive and capital-intensive biotechnology sector, specifically targeting neurodegenerative and rare amyloid diseases. The advancement of multiple programs into late-stage clinical trials (Phase 3 for Parkinson's and ATTR amyloidosis) with major pharmaceutical partners like Roche and Novo Nordisk is a significant de-risking event, aligning with industry trends of large pharma seeking innovative assets through partnerships. The focus on protein dysregulation and proprietary CYTOPE technology positions Prothena at the forefront of addressing complex disease mechanisms, a key area of unmet medical need.

Comparison to Industry Standards

• Roche's projection of prasinezumab's peak sales potential greater than $3.5 billion positions it as a potential blockbuster drug, comparable to other leading therapies in neurodegenerative diseases.
• The advancement of coramitug by Novo Nordisk, following its up to $1.2 billion acquisition of Prothena's ATTR amyloidosis business, reflects a valuation consistent with high-potential assets in rare disease markets, similar to other significant M&A activities in the biotech space.
• BMS-986446 receiving Fast Track designation from the U.S. FDA for Alzheimer's disease is a common regulatory acceleration for promising therapies in areas of high unmet need, similar to designations granted to other Alzheimer's drug candidates.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for capital return via a share redemption program in 2026; long-term value creation through advancing clinical pipeline and potential milestone payments.
• Employees: Reduction in workforce announced in June 2025 (related to restructuring charges) indicates some impact on employment.
• Patients: Advancement of multiple investigational therapeutics for devastating neurodegenerative and rare amyloid diseases offers hope for new treatment options.
• Partners (Roche, Novo Nordisk, Bristol Myers Squibb): Continued collaboration and progress in joint development programs.

Next Steps

• Bristol Myers Squibb to decide on the potential advancement of PRX019 in 2026.
• Completion of the Phase 1 clinical trial for PRX019 expected in 2026.
• Potential clinical milestone from Novo Nordisk for coramitug in 1H 2026.
• Potential clinical milestone for PRX019 by end of 2026.
• Share more data from preclinical programs later in 2026.
• Senior management to present at The Citizens Life Sciences Conference on March 11, 2026.
• Potential share redemption program in 2026.
• Primary completion of Phase 2 TargetTau-1 trial expected in 1H 2027.
• Primary completion of Phase 3 PARAISO trial expected in 2029.
• Primary completion of Phase 3 CLEOPATTRA trial expected in 2029.

Key Dates

Recommendation

While Prothena demonstrated significant progress in advancing its clinical pipeline with multiple programs entering late-stage trials and securing FDA Fast Track designation, the substantial increase in net loss and decrease in revenue for 2025, albeit partly due to one-off items and the absence of a large upfront payment, warrant caution. The potential for future milestone payments and a share redemption program are positive, but the long development timelines for biotech assets and inherent clinical risks suggest a "Hold" recommendation until further clarity on financial performance and clinical outcomes emerges.

Keywords

Prothena, PRTA, biotechnology, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, ATTR amyloidosis, clinical trials, Phase 3, Phase 2, financial results, Q4 2025, FY 2025, prasinezumab, coramitug, BMS-986446, PRX019, TDP-43 CYTOPE, PRX012-TfR, Roche, Novo Nordisk, Bristol Myers Squibb, FDA Fast Track, share redemption, cash guidance